Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Enzalutamide Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors.

Udhane V, Maranto C, Hoang DT, Gu L, Erickson A, Devi S, Talati PG, Banerjee A, Iczkowski KA, Jacobsohn K, See WA, Mirtti T, Kilari D, Nevalainen MT.

Mol Cancer Ther. 2019 Sep 23. pii: molcanther.0508.2019. doi: 10.1158/1535-7163.MCT-19-0508. [Epub ahead of print]

PMID:
31548294
2.

Tumor expression of human chorionic gonadotropin beta mRNA and prognosis of prostate cancer treated by radical prostatectomy.

Lintula S, Mirtti T, Rannikko A, Bützow A, Lempiäinen A, Stenman J, Stenman UH, Hotakainen K.

Scand J Clin Lab Invest. 2019 Oct;79(6):424-430. doi: 10.1080/00365513.2019.1639214. Epub 2019 Jul 11.

PMID:
31294620
3.

Positive STAT5 Protein and Locus Amplification Status Predicts Recurrence after Radical Prostatectomy to Assist Clinical Precision Management of Prostate Cancer.

Haddad BR, Erickson A, Udhane V, LaViolette PS, Rone JD, Kallajoki MA, See WA, Rannikko A, Mirtti T, Nevalainen MT.

Cancer Epidemiol Biomarkers Prev. 2019 Oct;28(10):1642-1651. doi: 10.1158/1055-9965.EPI-18-1358. Epub 2019 Jul 10.

PMID:
31292140
4.

Fibroblast as a critical stromal cell type determining prognosis in prostate cancer.

Blom S, Erickson A, Östman A, Rannikko A, Mirtti T, Kallioniemi O, Pellinen T.

Prostate. 2019 Sep;79(13):1505-1513. doi: 10.1002/pros.23867. Epub 2019 Jul 3.

5.

Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: A prospective multi-institutional trial.

Jambor I, Verho J, Ettala O, Knaapila J, Taimen P, Syvänen KT, Kiviniemi A, Kähkönen E, Perez IM, Seppänen M, Rannikko A, Oksanen O, Riikonen J, Vimpeli SM, Kauko T, Merisaari H, Kallajoki M, Mirtti T, Lamminen T, Saunavaara J, Aronen HJ, Boström PJ.

PLoS Med. 2019 Jun 3;16(6):e1002813. doi: 10.1371/journal.pmed.1002813. eCollection 2019 Jun.

6.

Fast prostate retrieval in robot-assisted laparoscopic prostatectomy for next-generation biobanking.

Petas A, Erickson A, Santti H, Matikainen M, Mirtti T, Rannikko A.

J Robot Surg. 2019 May 25. doi: 10.1007/s11701-019-00974-7. [Epub ahead of print]

PMID:
31129776
7.

Patient Experience of Systematic Versus Fusion Prostate Biopsies.

Eineluoto JT, Järvinen P, Kilpeläinen T, Lahdensuo K, Kalalahti I, Sandeman K, Mirtti T, Rannikko A.

Eur Urol Oncol. 2018 Aug;1(3):202-207. doi: 10.1016/j.euo.2018.02.005. Epub 2018 May 15.

PMID:
31102622
8.

Cumulative Cancer Locations is a Novel Metric for Predicting Active Surveillance Outcomes: A Multicenter Study.

Erickson AM, Luzzago S, Semjonow A, Vasarainen H, Laajala TD, Musi G, de Cobelli O, Mirtti T, Rannikko A.

Eur Urol Oncol. 2018 Sep;1(4):268-275. doi: 10.1016/j.euo.2018.04.006. Epub 2018 May 15.

PMID:
31100247
9.

SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer.

Stranne J, Brasso K, Brennhovd B, Johansson E, Jäderling F, Kouri M, Lilleby W, Meidahl Petersen P, Mirtti T, Pettersson A, Rannikko A, Thellenberg C, Akre O.

Scand J Urol. 2018 Oct - Dec;52(5-6):313-320. doi: 10.1080/21681805.2018.1520295. Epub 2018 Dec 26.

PMID:
30585526
10.

Metformin increases glucose uptake and acts renoprotectively by reducing SHIP2 activity.

Polianskyte-Prause Z, Tolvanen TA, Lindfors S, Dumont V, Van M, Wang H, Dash SN, Berg M, Naams JB, Hautala LC, Nisen H, Mirtti T, Groop PH, Wähälä K, Tienari J, Lehtonen S.

FASEB J. 2019 Feb;33(2):2858-2869. doi: 10.1096/fj.201800529RR. Epub 2018 Oct 15.

11.

Increased HSF1 expression predicts shorter disease-specific survival of prostate cancer patients following radical prostatectomy.

Björk JK, Ahonen I, Mirtti T, Erickson A, Rannikko A, Bützow A, Nordling S, Lundin J, Lundin M, Sistonen L, Nees M, Åkerfelt M.

Oncotarget. 2018 Jul 27;9(58):31200-31213. doi: 10.18632/oncotarget.25756. eCollection 2018 Jul 27.

12.

Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient-derived cancer cells.

Saeed K, Ojamies P, Pellinen T, Eldfors S, Turkki R, Lundin J, Järvinen P, Nisen H, Taari K, Af Hällström TM, Rannikko A, Mirtti T, Kallioniemi O, Östling P.

Int J Cancer. 2019 Mar 15;144(6):1356-1366. doi: 10.1002/ijc.31815. Epub 2018 Nov 4.

PMID:
30125350
13.

New prostate cancer grade grouping system predicts survival after radical prostatectomy.

Erickson A, Sandeman K, Lahdensuo K, Nordling S, Kallajoki M, Seikkula H, Bützow A, Vasarainen H, Boström PJ, Taimen P, Rannikko A, Mirtti T.

Hum Pathol. 2018 May;75:159-166. doi: 10.1016/j.humpath.2018.01.027. Epub 2018 Feb 13. No abstract available.

14.

ITGB1-dependent upregulation of Caveolin-1 switches TGFβ signalling from tumour-suppressive to oncogenic in prostate cancer.

Pellinen T, Blom S, Sánchez S, Välimäki K, Mpindi JP, Azegrouz H, Strippoli R, Nieto R, Vitón M, Palacios I, Turkki R, Wang Y, Sánchez-Alvarez M, Nordling S, Bützow A, Mirtti T, Rannikko A, Montoya MC, Kallioniemi O, Del Pozo MA.

Sci Rep. 2018 Feb 5;8(1):2338. doi: 10.1038/s41598-018-20161-2.

15.

Repeat multiparametric MRI in prostate cancer patients on active surveillance.

Eineluoto JT, Järvinen P, Kenttämies A, Kilpeläinen TP, Vasarainen H, Sandeman K, Erickson A, Mirtti T, Rannikko A.

PLoS One. 2017 Dec 27;12(12):e0189272. doi: 10.1371/journal.pone.0189272. eCollection 2017.

16.

Metabolomic Profiling of Extracellular Vesicles and Alternative Normalization Methods Reveal Enriched Metabolites and Strategies to Study Prostate Cancer-Related Changes.

Puhka M, Takatalo M, Nordberg ME, Valkonen S, Nandania J, Aatonen M, Yliperttula M, Laitinen S, Velagapudi V, Mirtti T, Kallioniemi O, Rannikko A, Siljander PR, Af Hällström TM.

Theranostics. 2017 Aug 23;7(16):3824-3841. doi: 10.7150/thno.19890. eCollection 2017.

17.

Feasibility of Prostate PAXgene Fixation for Molecular Research and Diagnostic Surgical Pathology: Comparison of Matched Fresh Frozen, FFPE, and PFPE Tissues.

Högnäs G, Kivinummi K, Kallio HML, Hieta R, Ruusuvuori P, Koskenalho A, Kesseli J, Tammela TLJ, Riikonen J, Ilvesaro J, Kares S, Hirvikoski PP, Laurila M, Mirtti T, Nykter M, Kujala PM, Visakorpi T, Tolonen T, Bova GS.

Am J Surg Pathol. 2018 Jan;42(1):103-115. doi: 10.1097/PAS.0000000000000961.

PMID:
28984675
18.

Immunological tumor status may predict response to neoadjuvant chemotherapy and outcome after radical cystectomy in bladder cancer.

Tervahartiala M, Taimen P, Mirtti T, Koskinen I, Ecke T, Jalkanen S, Boström PJ.

Sci Rep. 2017 Oct 4;7(1):12682. doi: 10.1038/s41598-017-12892-5.

19.

A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale.

Auvinen A, Rannikko A, Taari K, Kujala P, Mirtti T, Kenttämies A, Rinta-Kiikka I, Lehtimäki T, Oksala N, Pettersson K, Tammela TL.

Eur J Epidemiol. 2017 Jun;32(6):521-527. doi: 10.1007/s10654-017-0292-5. Epub 2017 Jul 31.

PMID:
28762124
20.

PTEN Loss but Not ERG Expression in Diagnostic Biopsies Is Associated with Increased Risk of Progression and Adverse Surgical Findings in Men with Prostate Cancer on Active Surveillance.

Lokman U, Erickson AM, Vasarainen H, Rannikko AS, Mirtti T.

Eur Urol Focus. 2018 Dec;4(6):867-873. doi: 10.1016/j.euf.2017.03.004. Epub 2017 Mar 22.

21.
22.

Erratum: Longitudinal modeling of ultrasensitive and traditional prostate-specific antigen and prediction of biochemical recurrence after radical prostatectomy.

Laajala TD, Seikkula H, Seyednasrollah F, Mirtti T, Boström PJ, Elo LL.

Sci Rep. 2017 Jan 19;7:40835. doi: 10.1038/srep40835. No abstract available.

23.

Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data.

Guinney J, Wang T, Laajala TD, Winner KK, Bare JC, Neto EC, Khan SA, Peddinti G, Airola A, Pahikkala T, Mirtti T, Yu T, Bot BM, Shen L, Abdallah K, Norman T, Friend S, Stolovitzky G, Soule H, Sweeney CJ, Ryan CJ, Scher HI, Sartor O, Xie Y, Aittokallio T, Zhou FL, Costello JC; Prostate Cancer Challenge DREAM Community.

Lancet Oncol. 2017 Jan;18(1):132-142. doi: 10.1016/S1470-2045(16)30560-5. Epub 2016 Nov 16.

24.

Longitudinal modeling of ultrasensitive and traditional prostate-specific antigen and prediction of biochemical recurrence after radical prostatectomy.

Laajala TD, Seikkula H, Seyednasrollah F, Mirtti T, Boström PJ, Elo LL.

Sci Rep. 2016 Nov 2;6:36161. doi: 10.1038/srep36161. Erratum in: Sci Rep. 2017 Jan 19;7:40835.

25.

Outcome of surgery for patients with renal cell carcinoma and tumour thrombus in the era of modern targeted therapy.

Tornberg SV, Nisen H, Visapää H, Kilpeläinen TP, Järvinen R, Mirtti T, Kantonen I, Simpanen J, Bono P, Taari K, Järvinen P.

Scand J Urol. 2016 Oct;50(5):380-6. doi: 10.1080/21681805.2016.1217558.

PMID:
27603426
26.

Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy.

Lahdensuo K, Erickson A, Saarinen I, Seikkula H, Lundin J, Lundin M, Nordling S, Bützow A, Vasarainen H, Boström PJ, Taimen P, Rannikko A, Mirtti T.

Mod Pathol. 2016 Dec;29(12):1565-1574. doi: 10.1038/modpathol.2016.154. Epub 2016 Aug 26.

27.

Benefit of Adjuvant Chemotherapy and Pelvic Lymph Node Dissection in pT3 and Node Positive Bladder Cancer Patients Treated with Radical Cystectomy.

Boström PJ, Mirtti T, van Rhijn B, Fleshner NE, Finelli A, Laato M, Jewett MA, Moore MJ, Sridhar S, Nurmi M, Tannock IF, Zlotta AR.

Bladder Cancer. 2016 Apr 27;2(2):263-272.

28.

Hypoxia Marker GLUT-1 (Glucose Transporter 1) is an Independent Prognostic Factor for Survival in Bladder Cancer Patients Treated with Radical Cystectomy.

Boström PJ, Thoms J, Sykes J, Ahmed O, Evans A, van Rhijn BW, Mirtti T, Stakhovskyi O, Laato M, Margel D, Pintilie M, Kuk C, Milosevic M, Zlotta AR, Bristow RG.

Bladder Cancer. 2016 Jan 7;2(1):101-109.

29.

Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer.

Saeed K, Rahkama V, Eldfors S, Bychkov D, Mpindi JP, Yadav B, Paavolainen L, Aittokallio T, Heckman C, Wennerberg K, Peehl DM, Horvath P, Mirtti T, Rannikko A, Kallioniemi O, Östling P, Af Hällström TM.

Eur Urol. 2017 Mar;71(3):319-327. doi: 10.1016/j.eururo.2016.04.019. Epub 2016 May 6.

30.

Association of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma.

Rautiola J, Lampinen A, Mirtti T, Ristimäki A, Joensuu H, Bono P, Saharinen P.

PLoS One. 2016 Apr 21;11(4):e0153745. doi: 10.1371/journal.pone.0153745. eCollection 2016.

31.

Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.

Pouessel D, Neuzillet Y, Mertens LS, van der Heijden MS, de Jong J, Sanders J, Peters D, Leroy K, Manceau A, Maille P, Soyeux P, Moktefi A, Semprez F, Vordos D, de la Taille A, Hurst CD, Tomlinson DC, Harnden P, Bostrom PJ, Mirtti T, Horenblas S, Loriot Y, Houédé N, Chevreau C, Beuzeboc P, Shariat SF, Sagalowsky AI, Ashfaq R, Burger M, Jewett MA, Zlotta AR, Broeks A, Bapat B, Knowles MA, Lotan Y, van der Kwast TH, Culine S, Allory Y, van Rhijn BW.

Ann Oncol. 2016 Jul;27(7):1311-6. doi: 10.1093/annonc/mdw170. Epub 2016 Apr 18.

32.

Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy.

Yu L, Toriseva M, Tuomala M, Seikkula H, Elo T, Tuomela J, Kallajoki M, Mirtti T, Taimen P, Boström PJ, Alanen K, Nurmi M, Nees M, Härkönen P.

Int J Cancer. 2016 Jul 1;139(1):140-52. doi: 10.1002/ijc.30048. Epub 2016 Mar 12.

33.

The diagnostics of prostate cancer is changing.

Sandeman K, Rannikko A, Kenttämies A, Mirtti T.

Duodecim. 2016;132(24):2351-8.

PMID:
29199795
34.

Differential Predictive Roles of A- and B-Type Nuclear Lamins in Prostate Cancer Progression.

Saarinen I, Mirtti T, Seikkula H, Boström PJ, Taimen P.

PLoS One. 2015 Oct 15;10(10):e0140671. doi: 10.1371/journal.pone.0140671. eCollection 2015.

35.

Le Fibroblast Growth Factor Receptor 3 (FGFR3), cible thérapeutique pour le traitement personnalisé du cancer de la vessie : validation anatomo-pathologique du concept.

Neuzillet Y, Mertens L, Shariat S, Bostrom P, Mirtti T, Sagalowsky A, Ashfaq R, Broeks A, Van der Heijden M, Peters D, Curial C, De Jong J, Horenblas S, Hurst C, Tomlinson D, Knowles M, Bapat B, Jewett M, Zlotta A, Sanders J, Lotan Y, Van der Kwast T, Van Rhijn B.

Prog Urol. 2014 Nov;24(13):806-7. doi: 10.1016/j.purol.2014.08.054. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461579
36.

Tumor-Associated Macrophages Provide Significant Prognostic Information in Urothelial Bladder Cancer.

Boström MM, Irjala H, Mirtti T, Taimen P, Kauko T, Ålgars A, Jalkanen S, Boström PJ.

PLoS One. 2015 Jul 21;10(7):e0133552. doi: 10.1371/journal.pone.0133552. eCollection 2015.

37.

Rac1 nucleocytoplasmic shuttling drives nuclear shape changes and tumor invasion.

Navarro-Lérida I, Pellinen T, Sanchez SA, Guadamillas MC, Wang Y, Mirtti T, Calvo E, Del Pozo MA.

Dev Cell. 2015 Feb 9;32(3):318-34. doi: 10.1016/j.devcel.2014.12.019. Epub 2015 Jan 29.

38.

Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer.

Hoang DT, Gu L, Liao Z, Shen F, Talati PG, Koptyra M, Tan SH, Ellsworth E, Gupta S, Montie H, Dagvadorj A, Savolainen S, Leiby B, Mirtti T, Merry DE, Nevalainen MT.

Mol Cancer Ther. 2015 Mar;14(3):713-26. doi: 10.1158/1535-7163.MCT-14-0819. Epub 2014 Dec 31.

39.

Role of ultrasensitive prostate-specific antigen in the follow-up of prostate cancer after radical prostatectomy.

Seikkula H, Syvänen KT, Kurki S, Mirtti T, Taimen P, Laato M, Boström PJ.

Urol Oncol. 2015 Jan;33(1):16.e1-16.e7. doi: 10.1016/j.urolonc.2014.10.010. Epub 2014 Nov 18.

PMID:
25456996
40.

Androgen receptor-interacting protein HSPBAP1 facilitates growth of prostate cancer cells in androgen-deficient conditions.

Saeed K, Östling P, Björkman M, Mirtti T, Alanen K, Vesterinen T, Sankila A, Lundin J, Lundin M, Rannikko A, Nordling S, Mpindi JP, Kohonen P, Iljin K, Kallioniemi O, Rantala JK.

Int J Cancer. 2015 Jun 1;136(11):2535-45. doi: 10.1002/ijc.29303. Epub 2014 Nov 20.

41.

Performance of transrectal prostate biopsies in detecting tumours and implications for focal therapy.

Lahdensuo K, Mirtti T, Petas A, Rannikko A.

Scand J Urol. 2015 Apr;49(2):90-6. doi: 10.3109/21681805.2014.936494. Epub 2014 Jul 16.

PMID:
25028807
42.

Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation.

Gu L, Talati P, Vogiatzi P, Romero-Weaver AL, Abdulghani J, Liao Z, Leiby B, Hoang DT, Mirtti T, Alanen K, Zinda M, Huszar D, Nevalainen MT.

Mol Cancer Ther. 2014 May;13(5):1246-58. doi: 10.1158/1535-7163.MCT-13-0605. Epub 2014 Feb 27.

43.

STAT5A/B gene locus undergoes amplification during human prostate cancer progression.

Haddad BR, Gu L, Mirtti T, Dagvadorj A, Vogiatzi P, Hoang DT, Bajaj R, Leiby B, Ellsworth E, Blackmon S, Ruiz C, Curtis M, Fortina P, Ertel A, Liu C, Rui H, Visakorpi T, Bubendorf L, Lallas CD, Trabulsi EJ, McCue P, Gomella L, Nevalainen MT.

Am J Pathol. 2013 Jun;182(6):2264-75. doi: 10.1016/j.ajpath.2013.02.044. Epub 2013 May 7.

44.

Nuclear Stat5a/b predicts early recurrence and prostate cancer-specific death in patients treated by radical prostatectomy.

Mirtti T, Leiby BE, Abdulghani J, Aaltonen E, Pavela M, Mamtani A, Alanen K, Egevad L, Granfors T, Josefsson A, Stattin P, Bergh A, Nevalainen MT.

Hum Pathol. 2013 Mar;44(3):310-9. doi: 10.1016/j.humpath.2012.06.001. Epub 2012 Sep 29.

45.

Upper urinary tract and urethral recurrences following radical cystectomy: review of risk factors and outcomes between centres with different follow-up protocols.

Perlis N, Turker P, Bostrom PJ, Kuk C, Mirtti T, Kulkarni G, Fleshner NE, Jewett MA, Finelli A, Zlotta AR.

World J Urol. 2013 Feb;31(1):161-7. doi: 10.1007/s00345-012-0905-2. Epub 2012 Jul 19.

PMID:
22810052
46.

High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer.

Vainio P, Mpindi JP, Kohonen P, Fey V, Mirtti T, Alanen KA, Perälä M, Kallioniemi O, Iljin K.

PLoS One. 2012;7(6):e39801. doi: 10.1371/journal.pone.0039801. Epub 2012 Jun 28.

47.

Does patient age affect survival after radical cystectomy?

Horovitz D, Turker P, Bostrom PJ, Mirtti T, Nurmi M, Kuk C, Kulkarni G, Fleshner NE, Finelli A, Jewett MA, Zlotta AR.

BJU Int. 2012 Dec;110(11 Pt B):E486-93. doi: 10.1111/j.1464-410X.2012.11180.x. Epub 2012 May 2.

48.

Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome.

Turker P, Bostrom PJ, Wroclawski ML, van Rhijn B, Kortekangas H, Kuk C, Mirtti T, Fleshner NE, Jewett MA, Finelli A, Kwast TV, Evans A, Sweet J, Laato M, Zlotta AR.

BJU Int. 2012 Sep;110(6):804-11. doi: 10.1111/j.1464-410X.2012.10939.x. Epub 2012 Feb 9.

49.

Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins.

Vainio P, Lehtinen L, Mirtti T, Hilvo M, Seppänen-Laakso T, Virtanen J, Sankila A, Nordling S, Lundin J, Rannikko A, Orešič M, Kallioniemi O, Iljin K.

Oncotarget. 2011 Dec;2(12):1176-90.

50.

Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion.

Björkman M, Östling P, Härmä V, Virtanen J, Mpindi JP, Rantala J, Mirtti T, Vesterinen T, Lundin M, Sankila A, Rannikko A, Kaivanto E, Kohonen P, Kallioniemi O, Nees M.

Oncogene. 2012 Jul 19;31(29):3444-56. doi: 10.1038/onc.2011.512. Epub 2011 Nov 28.

PMID:
22120715

Supplemental Content

Loading ...
Support Center